eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2024
vol. 11
 
Share:
Send email
Share:
abstract:
Case report

Efficacy of hydroxychloroquine and omalizumab in a patient with systemic lupus erythematosus, Hashimoto thyroiditis and refractory chronic spontaneous urticaria

Öner Özdemir
1
,
Ümmügülsüm Dikici
1
,
Sena Sultan Karaca
2

  1. Division of Pediatric Immunology and Allergy, Sakarya Training and Research Hospital, Sakarya University Medical Faculty, Sakarya, Türkiye
  2. Sakarya University Medical Faculty, Sakarya Training and Research Hospital, Sakarya, Türkiye
Alergologia Polska – Polish Journal of Allergology 2024; 11, 4: 335–338
DOI: https://doi.org/10.5114/pja.2024.145187
Online publish date: 2024/11/21
View full text Get citation
 
PlumX metrics:
A 15-year-old girl was admitted to an external center 1 month ago with symptoms of generalized pruritus, rash and blistering all over the body, and swelling of the eyes and lips. The patient was started on desloratadine, but there was no improvement in her symptoms. She had been diagnosed with Hashimoto’s thyroiditis 4 years ago in the pediatric endocrinology department; she had been using levothyroxine since then, and her thyroid disease was under control. The dose of antihistamine treatment was increased and montelukast was added. The patient, who had Raynaud’s phenomenon, was diagnosed with systemic lupus erythematosus and hydroxychloroquine was started, but the symptoms of urticaria and angioedema did not decrease. The patient was then started on omalizumab and urticaria was controlled under hydroxychloroquine + omalizumab. In the third month of omalizumab discontinuation, the patient is receiving hydroxychloroquine and levothyroxine treatments and continues to be followed up, being in remission in terms of chronic spontaneous urticaria.
keywords:

systemic lupus erythematosus, Hashimoto’s thyroiditis, chronic spontaneous urticaria, omalizumab, hydro­xychloroquine


Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.